NicOx Submits NDA for Osteoarthritis Drug, But Still Seeks a Commercial Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
NicOx hopes a U.S. commercial partner for naproxcinod will target primary care physicians, leaving French biotech to address specialists.
You may also be interested in...
Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?
FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.
Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?
FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.
NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate
Deal shows - once again - that all is not lost when Big Pharma hands back a product